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Abstract
Background: Exhaled breath condensate (EBC) is thought to contain substances of the lower airway epithelial lining ﬂ  uid 
(ELF) aerosolized by turbulent ﬂ  ow. However, contamination by saliva may affect the EBC when collected orally.
Objective: The purpose of this study was to compare the cytokine expression levels in EBC with those in saliva, and to 
clarify the inﬂ  uence of saliva on cytokine measurements of EBC.
Methods: EBC and saliva samples were obtained from 10 adult subjects with stable asthma. To estimate differences in the 
contents of substances between EBC and saliva, the total protein concentration of each sample was measured. Further, we 
also measured the total protein concentration of ELF obtained from another patient group with suspected lung cancer using 
a micro sampling probe during bronchoscopic examination and roughly estimated the dilution of EBC by comparing the 
total protein concentration of EBC and ELF from those two patient groups. The cytokine expression levels of EBC and 
saliva from asthmatic group were assessed by a cytokine protein array.
Results: The mean total protein concentrations in EBC, saliva and ELF were 4.6 µg/ml, 2,398 µg/ml and 14,111 µg/ml, 
respectively. The dilution of EBC could be estimated as 1:3000. Forty cytokines were analyzed by a cytokine protein array 
and each cytokine expression level of EBC was found to be different from that of saliva. Corrected by the total protein 
concentration, all cytokine expression levels of EBC were signiﬁ  cantly higher than those of saliva.
Conclusion: These results suggest that the salivary inﬂ  uence on the cytokine assessment in EBC may be negligible.
Keywords: asthma, cytokine, chemokine, growth factor, epithelial lining ﬂ  uid
Introduction
Exhaled breath condensate (EBC) is collected by cooling exhaled air. Collecting EBC is a noninvasive 
and repeatable method, and many researchers have reported the usefulness of EBC for measuring airway 
inﬂ  ammatory molecules in respiratory diseases such as asthma, chronic obstructive pulmonary disease 
(COPD) and cystic ﬁ  brosis (Kharitonov and Barnes, 2004; Liu, J and Thomas, 2005; Barnes et al. 2006). 
EBC potentially reﬂ  ects the volatile and non-volatile substances derived from all the airways. Non-
volatile substances in airway epithelial lining ﬂ  uid (ELF) are thought to be aerosolized by the turbulent 
ﬂ  ow generated mainly in the lower airway. Then, they are diluted by exhaled water vapor and incorpo-
rated into EBC. The dilution of EBC has been estimated using the conductivity, total cations and urea 
of plasma and EBC (Effros et al. 2004). When EBC is collected orally, it could contain substances 
derived from saliva (Silkoff et al. 2006). Some solutes measured in EBC such as amylase, and eico-
sanoids have been examined as markers of salivary contamination (Kharitonov and Barnes, 2001; 
Griese et al. 2002). The EBC pH from COPD patients has been reported to be unsuitable as a marker 
of airway acidiﬁ  cation because it is affected by the volatile salivary acid (Effros et al. 2006). Leukotrien 
B4 in EBC has been reported to be derived from saliva (Gaber et al. 2006). However, the proportional 
contribution of saliva on the cytokine assessment of EBC has not yet been sufﬁ  ciently studied.
Several molecules such as eicosanoids, chemokines and cytokines have been measured in EBC with the 
use of various assays such as a speciﬁ  c enzyme immunoassay (Shahid et al. 2002; Ko et al. 2006), gas 86
Ichikawa et al
Analytical Chemistry Insights 2007:2
chromatography/mass spectrometry (Cap et al. 
2004), and cytometry beads array (Sack, U et al. 
2006, Gessner et al. 2005). However, the precise 
molecular properties in EBC have not been clearly 
determined because the concentration of molecules 
measured in EBC is extremely low and there is 
relatively high variability in repeated measurements 
(Horvath et al. 2005; Hunt, 2002). We previously 
reported that a cytokine array assay was useful for 
cytokine analysis of EBC obtained from asthmatic 
patients (Matsunaga et al. 2006). Although this was 
a semiquantitative assay, the expression levels of 
forty cytokines could be simultaneously measured 
and we found that several cytokines, such as interleu-
kin (IL)-4, IL-8, IL-17, tumor necrosis factor-alpha 
(TNF-α), regulated upon activation, normal T-cell 
expressed (RANTES), interferon (IFN)-γ-inducible 
protein 10 (IP-10), transforming growth factor-beta 1 
(TGF-β1), macrophage inflammatory protein 
1 alpha (MIP-1α) and MIP-1β were more up-regu-
lated in EBC from asthmatic patients than in that 
from healthy controls (Matsunaga et al. 2006). 
However, the concern about the salivary inﬂ  uence 
on the results remains.
In the present study, we compared the cytokine 
expression levels in EBC with those in saliva to 
evaluate the inﬂ  uence of saliva on the cytokine 
measurements of EBC. Furthermore, we estimated 
the extent to which the contents in ELF and saliva 
contribute to EBC by comparing the total protein 
concentration of EBC and saliva from an asthmatic 
group with that of ELF from another patient group 
who had undergone bronchoscopic examination.
Materials and Methods
Study subjects
For EBC and saliva collection, adult patients with 
stable asthma were recruited. All patients met the 
American Thoracic Society criteria for asthma 
(The ofﬁ  cial statement of the American Thoracic 
Society, 1986). Stable asthma was deﬁ  ned as an 
absence of unsche duled physician visits for asthma 
care, unchanged use of asthma medication for 
maintenance therapy, and stable use of rescue 
medication for at least 4 weeks before sample col-
lection. The patients who used regular anti-asthmatic 
medications except inhaled corticosteroids, had 
oral diseases or were current smokers were 
excluded. Patients planning to have a broncho-
scopic examination were recruited for ELF 
collection. Patients with suspected infec  tious dis-
ease or high risk of bleeding were excluded. This 
study was approved by the ethics committee of 
Wakayama Medical University and all patients 
gave written informed consent.
Ten patients were recruited for each subject 
group. Among the asthmatic patients, seven required 
daily therapy with inhaled corticosteroids equivalent 
to a dose of 400 µg or more ﬂ  uticasone. Two patients 
were ex-smokers. Two patients had a hypertension 
and used antihyper tensive drugs. Among the patients 
for ELF collection, four were current smokers and 
four patients were ex-smokers. Two patients had 
stage II COPD without medication. Two patients 
had hypertension and one patient used antihyper-
tensive drugs. After bronchoscopic examinations, 
seven patients were diagnosed as having lung cancer 
(three patients as adenocarcinoma, three patients as 
non-small cell lung carcinoma, one patient as 
metastatic lung carcinoma) and three patients exhib-
ited no abnormal ﬁ  ndings. The characteristics of the 
study subjects are listed in Table 1.
Study design
This study was cross-sectional. Subjects with asthma 
attended the outpatient clinic at the Wakayama 
Medical Univer  sity Hospital on one occasion for 
clinical examination, spirome  try, and collection of 
both EBC and saliva samples. Subjects planning to 
have a bronchoscopic examination were admitted 
to the hospital and underwent spirometry and bron-
choscopic examination. Spirometry was performed 
the day before the broncoscopic examination.
EBC, saliva and ELF collection
The EBC was collected by using a condenser, 
which permitted noninvasive collection of con-
Table 1. Characteristics of study subjects.
  Asthmatics  ELF group  p value
Subject number  10  10 
Age(yr) 44.6 ± 5.4 63.1  ± 5.3 0.025
Sex   
female/male 5/5  1/9 
FVC(L) 3.35 ± 0.16 3.51  ± 0.29 0.824
FEV1 (L)  2.48 ± 0.18 2.55 ± 0.25 0.647
FEV1%(%) 73.9 ± 3.6 74.2 ± 5.1 0.960
%FEV1(%) 84.5 ± 6.5 87.9 ± 5.2 0.691
FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity values are means ±SE.87
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densed exhaled air by freezing it to –20 °C (Eco-
screen; Jaeger, Hoechberg, Germany) (Montuschi 
et al. 2000). The subjects breathed through a 
mouthpiece and a two-way non-rebreathing valve, 
which also served as a saliva trap. Subjects were 
asked to breath at a normal frequency and tidal 
volume, wearing a nose-clip, for 20–30 minutes. 
The collected EBC was melted and transferred to 
1 ml Eppendorf tubes and immediately stored at 
–80 °C until investigation. The mean volume col-
lected was approximately 2–3 ml.
Saliva was collected by expectoration into plas-
tic tubes following EBC collection. Collected 
saliva samples were centrifuged at 300 g for 5 
minutes and the separated supernatant was stored 
at –80 °C until investigation.
ELF samples were collected using bronchos-
copy with microsam pling probes (model BC-402C; 
Olympus, Tokyo, Japan) as previously described 
(Yamazaki et al. 2003). Brieﬂ  y, the probe com-
prised a 2.5 mm outer diameter polyethylene sheath 
and an inner 1.9 mm-polyester ﬁ  ber rod probe 
attached to a stainless steel guide wire. This probe 
immediately absorbs ﬂ  uid. A ﬂ  exible ﬁ  beroptic 
bronchoscope (model BF-P240; Olympus) was 
inserted into the right or left main bronchus after 
local anesthesia of the upper respiratory tract was 
achieved with a few millili  ters of 2–4% lidocaine. 
After the channel of the bronchoﬁ  berscope was 
ﬂ  ushed with air, the microsampling probe was 
inserted through the channel into a main bronchus. 
Then, the inner probe was advanced slowly into 
the airway, and sampling of ELF was performed 
by placing the probe gently at a site of the targeted 
bronchial wall for 10 seconds. To avoid blood 
contamination, the subject was asked to hold a 
breath while the inner probe was placed at the 
bronchus. The inner probe was withdrawn into the 
outer tube, and both devices were withdrawn 
simultaneously. If visible blood contamination on 
the inner probe was detected, we inserted a micro-
sampling probe again and recollected the ELF 
sample. The wet inner probe was cut 2cm from its 
tip. Three collected tips were placed in a tube and 
centrifuged at 10,000g for 10min. The solution was 
transferred to a new tube and stored at –80 °C until 
investiga tion. The probe was the dried and weighed 
again to measure the ELF volume recovered.
Cytokine assessment and detection of the pro-
tein concentration were performed within 4 weeks 
after collection of the EBC, saliva and ELF 
samples.
Cytokine measurements
Human Inﬂ  ammation Antibody III (Ray Biotech 
Inc., Norcross, Ga, U.S.A.), consisting of 40 
different cytokine and chemokine antibodies spotted 
in duplicate onto a membrane, was utilized (Huang, 
2001a; Huang, 2001b; Lin et al. 2003; Turtinen 
et al. 2004). Brieﬂ  y, the membranes were blocked 
with 10% bovine serum albumin in Tris-buffered 
saline, and then 1.0 ml each of EBC and saliva 
obtained from the asthmatic subjects was added to 
each membrane and incubated at room temperature 
for 2 hours. The membranes were washed, and 
1.0 ml of primary biotin-conjugated antibody was 
added and incubated at room temperature for 
2 hours. Following a thorough wash, the membranes 
were incubated with 2.0 ml of horseradish peroxi-
dase (HRP)-conjugated streptavidin at room tem-
perature for 1 hour. The intensity of signals was 
detected directly from the membranes using a che-
miluminescene imaging system (Luminocapture 
AE6955; Atto Co., Tokyo, Japan). Exposure times 
ranged from 30 seconds to 2 minutes. Chemilumi-
nescence was quantiﬁ  ed with Atto imaging and 
analysis software. HRP-conjugated antibody served 
as a positive control at six spots and was also used 
to identify the membrane orientation. For each spot, 
the net intensity gray level was determined by sub-
stracting the background gray levels from the total 
raw intensity gray levels. The relative intensity 
levels of the cytokines were normalized with refer-
ence to the amounts of cytokines present on the 
positive control in each membrane on the following 
basis: average of the cytokine spot intensity levels/
average of the positive control spot intensity levels, 
indicated as a percentage. Both the cytokine detec-
tion level and the within-subjects reproducibility of 
this array have been described in a previous report 
(Matsunaga et al. 2006).
Total protein measurements in EBC, 
saliva, and ELF
The total protein concentrations of the saliva and 
ELF samples were measured with a Bradford protein 
assay kit (Bio-Rad, Hercules, CA, U.S.A.) (Bradford 
1976). The protein concentration of EBC was mea-
sured with a Micro BCA Protein Assay kit (Pierce, 
Rockford, IL, U.S.A.) (Smith et al. 1985).
Pulmonary function
Forced expiratory volume in one second (FEV1) 
and forced vital capacity (FVC) were measured 88
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with a Vitalograph Pneumotrac 6800TM 
(Vitarograph Co., Ennis, Ireland) according to a 
standard procedure (Standardization of Spirometry, 
1994).
Statistical analysis
Statistical analysis was performed using the statis-
tical software package Stat View (Abacus Concepts, 
Berkley, CA). Comparisons of the characteristics 
between two groups (asthmatic groups and ELF 
group) were performed by the Student’s t-test. 
Comparisons of the total protein concentration 
between EBC and saliva were performed by the 
Paired t-test. Comparisons of cytokine expression 
levels between EBC and saliva were performed by 
the Wilcoxon signed-ranks test. The results were 
reported as means ± SE except cytokine expression 
levels. Each cytokine expression level was 
expressed as median (interquartile range (IQR)). 
Significance was defined as a p value of less 
than 0.05.
Results
Total protein concentration
The total protein concentration was detectable in all 
EBC, saliva, and ELF samples. The mean total 
protein concentrations of EBC, saliva and ELF were 
4.6 ± 1.1 µg/ml, 2,398 ± 379 µg/ml and 14,111 ± 
3,477 µg/ml, respectively (Table 2). The ratio of the 
total protein concentration between EBC, saliva, 
and ELF was approximately 1:500:3000.
Comparison of the cytokine expression 
levels between EBC and saliva
The expression levels of each cytokine in EBC and 
saliva are shown in Table 3. The cytokines were 
lined up in the order of their expression levels in 
EBC with the highest level ﬁ  rst. The cytokine order 
of saliva was lined up to match that of EBC. Eotaxin, 
eotaxin-2, granulocyte-colony stimulating factor 
(G -CSF) and granulocyte-macrophage colony 
stimulating factor (GM -CSF) showed signiﬁ  cantly 
higher expression levels in EBC than in saliva 
(eotaxin: p = 0.013, eotaxin-2: p = 0.037, G-CSF, 
GM-CSF: p = 0.028). In contrast, the expression 
levels of IL-8, tissue inhibitor of metalloproteinases-
2 (TIMP2), IL-1β, monocyte chemoattractant pro-
tein 1 (MCP-1), soluble TNF recep tor I (sTNF-RI), 
intercellular adhesion molecule 1 (ICAM-1) and 
IL-7 were significantly higher in saliva (IL-8, 
TIMP2, MCP-1: p = 0.005, sTNF-RI, ICAM-1: 
p = 0.009, IL-1β: p = 0.017, IL-7: p = 0.047). The 
differences in the other cytokines between saliva 
and EBC were not signiﬁ  cant.
Comparison of the cytokine expression 
levels between EBC and saliva cor-
rected by the total protein contents
After correction by the total protein contents, the 
expres  sion levels of all cytokine in EBC were sig-
niﬁ  cantly higher than those in saliva. Especially, seven 
cytokines (IL-8, TIMP-2, sTNF-RI, MCP-1, IL-1β, 
ICAM-1 and IL-7), which were more up-regulated in 
saliva than in EBC before protein correc  tion, also 
showed signiﬁ  cantly higher expression levels in EBC 
than in saliva (Figs. 1A and 1B). Likewise, the cor-
rected expression levels of the eight cytokines (IL-4, 
IL-17, TNF-α, RANTES, IP-10, TGF-β1, MIP-1α 
and MIP-1β), which had been reported to be more 
up-regulated in EBC from asthmatics (Matsunaga K 
et al. 2006), were signiﬁ  cantly higher in EBC than in 
saliva (Figs. 1C and 1D).
Discussion
In the present study, EBC and saliva were found 
to have different levels cytokine expression. 
Among the examined molecules, eotaxin, eotaxin-2, 
GM-CSF and G-CSF were signiﬁ  cantly more up-
regulated in EBC than in saliva, although the total 
protein concentration of saliva was 500 times 
higher than that of EBC. Corrected by the total 
protein contents of the EBC and saliva, all cytokine 
expression levels measured in this study were 
signiﬁ  cantly higher in EBC than in saliva. These 
data suggest that the effect of salivary contamina-
tion on the cytokine assessment in EBC would be 
Table 2. Total protein concetration of each sample.
 EBC  Saliva  ELF
total protein  4.6 ± 1.1 2,398 ± 379* 14,111  ± 3,477
**†
concentration    
(µg/ml)
The samples of both EBC and saliva were obtained from the same 
asthmatic patients. ELF samples were obtained from another 
subject group who had undergone bronchoscopic examination. 
The ratio of the total protein concentration between EBC, saliva, 
and ELF was approximately 1:500:3000. *P = 0.0001 compared 
with the value of EBC **P = 0.0007 compared with the value of 
EBC 
†P = 0.0036 compared with the value of saliva. Values are 
means ± SE.89
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very small and that the main contributor to EBC 
cytokines would be ELF.
The inﬂ  uence of salivary contamination on EBC 
has been examined in several studies (Griese et al. 
2002; Gaber et al. 2006; Horvath et al. 2005; Mutlu 
et al. 2001; Effros et al. 2002). Amylase activity was 
once recommended to be measured routinely for 
monitoring the salivary contamination. However, 
amylase is not speciﬁ  c to saliva and at present the 
routine measurement of amylase activity is not 
recommended. The electrolyte ratios in saliva have 
been reported to differ from those in EBC (Effros 
et al. 2002). Further, EBC has been shown to contain 
proteins not present in saliva using two-dimensional 
gel electrophoresis (Griese et al. 2002). Thus, saliva 
has not been considered to be a major contributor 
to EBC. However, the inﬂ  uence of salivary con-
tamination on the assessment of inflammatory 
Table 3. Each cytokine expression level in ebc and saliva.
Cytokines  EBC(%)  Saliva(%)  p value  Cytokines  EBC(%)  Saliva(%)  p value
TNF-β 41.4  43.8  0.721  IL-16  10.3  11.4  0.386
 (36.6–51.6)  (33.8–52.6)      (8.5–21.9)  (3.5–17.2)
IP-10 37.0 36.6  0.575  M-CSF  10.3 12.4  0.139
 (28.0–37.9)  (28.2–50.1)      (8.1–14.2)  (8.9–21.8)
TNF-α 34.3  32.9  0.333  GCSF 9.9  5.6  0.028
 (25.9–43.8)  (24.8–46.3)      (5.2–12.1)  (2.3–6.9)
RANTES 25.8  29.7  0.575 IL-2  9.9  10.9  0.799
 (21.4–44.5)  (15.9–49.2)      (8.0–26.9)  (4.4–22.1)
TGF-β1 21.8  24.0  0.959  MIP-1α 9.6  18.1  0.575
 (16.3–31.5)  (14.3–36.8)      (8.2–16.8)  (7.1–19.5)
MIP-1β 20.8  32.9  0.241  MCP-1 8.7  51.2  0.005
 (16.8–30.3)  (19.6–52.4)      (6.8–15.1)  (38.7–62.5)
IL-15 15.9 11.5  0.114  IL-17  8.2  6.1  0.386
 (6.2–26.6)  (5.4–14.3)      (5.1–10.5)  (5.4–7.1)
EOTAXIN2 15.5  12.4  0.037  IL-1β 7.9  56.3  0.017
 (14.5–23.0)  (5.4–20.3)      (4.6–20.9)  (9.3–199.6)
IL-8 15.5  174.8  0.005  IL-6  6.9 5.9  0.386
 (12.2–19.7)  (108.1–358.8)      (4.4–9.4)  (2.4–7.9)
PDGF-BB 14.0  16.8  0.386  MIG  6.7  8.7  0.333
 (10.6–17.5)  (11.3–23.2)      (5.0–6.9)  (4.4–13.1)
IL-6sR 13.3  11.9  0.799  I-309  6.5  4.6  0.241
 (7.6–14.6)  (9.2–15.9)      (3.0–8.0)  (1.3–7.3)
EOTAXIN 13.2  10.1  0.013  IL-12p40 4.8  8.1  0.799
 (10.5–21.8)  (5.4–17.8)      (3.4–7.2)  (2.9–12.3)
sTNF R II  13.1  16.2  0.386  IFN-γ 4.7  5.1  0.093
 (10.5–14.1)  (13.5–19.0)      (4.2–11.3)  (1.4–6.7)
TIMP-2 12.9  56.7  0.005  GM-CSF  4.6  2.3  0.028
 (9.0–15.7)  (48.2–110.4)      (3.2–5.6)  (1.8–4.8)
IL-10 12.5 18.6  0.093  IL-13  4.6  5.4  0.508
 (10.0–20.6)  (13.1–25.0)      (1.6–13.0)  (2.4–14.3)
MIP-1δ 12.5  19.3  0.169  MCP-2  4.1  5.0  0.508
 (5.9–18.7)  (5.2–32.4)      (3.1–8.4)  (4.6–9.1)
IL-3 11.5  5.8  0.114  ICAM-1  4.0 14.9 0.009
 (7.0–21.5)  (3.6–13.8)      (2.9–6.1)  (13.4–19.0)
sTNF-R I  11.1  32.6  0.009  IL-7  3.3  5.4  0.047
 (10.6–19.3)  (20.6–45.9)      (2.3–5.4)  (4.3–9.1)
IL-1α 10.7 8.4  0.093  IL-12p70  3.0  4.8  0.721
 (7.7–18.2)  (2.3–12.6)      (2.0–5.4)  (0.3–9.7)
IL-4 10.4  8.7  0.241  IL-11  1.8 2.8  0.333
 (7.4–15.9)  (4.5–11.7)      (1.1–3.6)  (2.1–6.9)
Cytokines are lined up in the order of their expression levels in EBC with the highest ﬁ  rst. The cytokine order of saliva is lined up to match 
that of EBC. 
Abbreviations: Mig, Monokine induced by IFN-γ; IP-10, IFN-γ–in-ducible protein 10; MIP, Macrophage inﬂ  ammatory protein; IL-6sR, IL-6 
soluble receptor; M-CSF, macrophage colony-stimulating factor; PDGF, platelet-derived growth factor. Values are median (interquartile 
range).90
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molecules in EBC has not been fully investigated. 
Although Simpson JL et al. measured the IL-8 lev-
els in EBC and saliva samples from asthmatic 
patients, IL-8 was not measura  ble in all EBC sam-
ples and the detection level was almost near the 
detection limit of the assay. Furthermore, the sali-
vary inﬂ  uence on the IL-8 level in EBC was not 
assessed (Simpson et al. 2005). The salivary inﬂ  u-
ence on EBC cytokines has not been adequately 
clariﬁ  ed until now.
In the present study, the expression levels of 
several cytokines were found to be more up-
regulated in EBC than in saliva. As mentioned 
above, when cor rected by the total protein contents, 
the corrected cytokine expression levels of all cyto-
kines were signiﬁ  cantly higher in EBC than in 
saliva. This suggests that EBC and saliva might have 
different cytokine properties and the salivary 
inﬂ  uence on EBC cytokine might be negligibly 
small. A cytokine protein array is a semiquantitative 
Figure 1. Cytokine expression levels of EBC and saliva before and after correction by the total protein content. The expression levels of 
seven cytokines more up-regulated in saliva than in EBC (IL-8, TIMP-2, sTNF-RI, MCP-1, IL-1β, ICAM-1 and IL-7) (Fig. 1A), and the expres-
sion levels of eight cytokines which have been reported to be more up-regulated in EBC from asthmatic patients than healthy controls (Fig. 
1C) are shown. The expression levels of those cytokines corrected by the total protein content are shown (Figs. 1B and 1D). After protein 
correction, the expression levels of these cytokines were signiﬁ  cantly higher in EBC than in saliva (P = 0.0051). Values are median (inter-
quartile range).
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assay and the precise contribution of saliva is still 
unclear. However, it has been shown that the relative 
levels obtained by the protein array correlated well 
with the actual levels obtained by quantitative assays 
in several previous reports (Huang et al. 2002a; 
Huang et al. 2002b; Lin et al. 2003; Turtinen et al. 
2004) and our results should therefore be conducive 
to the standardization of EBC collec  tion.
Protein has been used as a dilution marker for EBC 
and BAL assessment (Jackson et al. 2007). As 
described in that report, protein may not be an ideal 
marker as a dilution parameter, but the protein can be 
readily measured with a small sample volume. In the 
present study, the sample volume of ELF was too low 
(10∼20 µl) and, therefore, we used it as a dilution 
marker of EBC. Although various markers such as 
conductivity, electrolyte and glucose have been mea-
sured to estimate the dilution of EBC, currently there 
is no deﬁ  nitive recommendation. The values of the 
total protein concentration of EBC from the present 
study groups were similar to those of previous reports 
(Effros et al. 2002; Effros et al. 2003). However, the 
values may be affected by the collecting device or 
breath condenser coatings. The concentrations of 
cysteinyl-Leukotriens and eotaxin were signiﬁ  cantly 
higher in EBC collected by ECoScreen than in that 
by RTube (Soyer et al. 2006). The albumin and 
8-isoprostane concentra tions of EBC differed among 
ﬁ  ve condenser coatings (Alfaro et al. 2007). Signiﬁ  -
cant differences in the thromboxane A(2) (TXA2) 
concentration of EBC and the detection rate of TXA2 
in EBC were found between enzyme immunoassay 
and radioimmunoassay (Huszar et al. 2005). Consider 
these technical effects on the EBC protein levels and 
further study will be needed for the standardization of 
EBC assessment.
The lower airways have been considered as the 
dominant source of non-volatile substances in 
EBC. The dilution of EBC has been estimated as 
approximately 1:2000∼1:20000 by comparing the 
conductivity and electrolyte concentration in EBC 
with those in plasma (Effros et al. 2002; Effros 
et al. 2003). The glucose concentration has been 
meas  ured in EBC to estimate the glucose concen-
tration in respiratory ﬂ  uid, although the glucose 
level in EBC is affected by the underlying disease 
such as diabetes and lung disease (Baker et al. 
2007). However, a direct comparison of the solute 
concentrations between EBC and the lower airway 
ELF has not been performed yet. Our report is the 
ﬁ  rst study in which a direct comparison between 
EBC and ELF were performed although samples 
were obtained from different groups. In the present 
study, the mean total protein concentration of ELF 
was found to be approximately 3,000 times higher 
than that of EBC, which suggests that the dilution 
of EBC could be estimated as 1:3000. In addition, 
the mean total protein concentration of ELF was 
six times higher than that of saliva. This indicates 
that the extent to which saliva would contribute to 
EBC should be very small compared with ELF. 
Our result supports the hypothesis that the domi-
nant source of non-volatile substances in EBC is 
the lower airway (Horvath et al. 2005) and previous 
reports that inﬂ  ammatory molecule analysis of 
EBC is useful for monitoring the asthmatic airway 
condition (Shaid et al. 2002; Ko et al. 2006; 
Matsunaga et al. 2006; Simpson et al. 2005).
In this study, we used the mean values of the total 
protein concentrations of EBC and ELF from dif-
ferent groups to roughly estimate the dilution of 
EBC and the expression levels of ELF, although 
there are some methodological problems. We didn’t 
perform a bronchoscopic examination for asthmatic 
pa  tients because such an examination could induce 
an asthma attack. Although the actual cytokine 
expression levels of ELF should have been mea-
sured, the sample volume of ELF was too low to be 
applied for a cytokine array assay. Furthermore, 
biomarkers such as 8-isoprostane, NOx, and H2O2 
in EBC were reported to be not correlated with those 
in bronchoalveolar lavage (BAL) (Jackson et al. 
2007). However, BAL is generally accepted as a 
sampling of only the smaller airways and alveoli. 
In this study, ELF was obtained from the larger 
airway (the right or left main bronchus). We previ-
ously reported that the albumin concentration of 
ELF obtained from COPD patients showed a strong 
correlation with %FEV1 and there was no signiﬁ  cant 
difference in the albumin levels according to the 
smoking status and age (Minakata et al. 2005). This 
suggests that the origin of EBC might be the central 
airways. Although subjects of ELF group in this 
study were signiﬁ  cantly older than those of the 
asthmatic group, there was no difference in the 
degree of airﬂ  ow limitation between the asthma and 
ELF groups. Thus, the mean total protein concentra-
tions of ELF from the ELF group can be expected 
to be similar to those of the asthmatic group. Accord-
ingly, we expect our result will be useful for future 
EBC studies despite its rough estima  tion.
In conclusion, the cytokine expression patterns 
of EBC and saliva were found to be different and 
the source of cytokines in EBC should be those 92
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from the lower airway. This suggests that the sali-
vary inﬂ  uence on the assessment of EBC cytokines 
would be negligibly small.
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